Psychiatric Times.
No. 8
Treating Eating Disorders: the Pitfalls and Perplexities
Arline Kaplan
August 1, 2004
During the 1980s, Halmi said the program had only five or six readmissions in the entire decade; now, one-third of admissions are readmissions. The limitations imposed by health maintenance organizations and managed care, she said, are often an "enormous detriment to the patients" and have resulted in higher relapse rates and more expensive care over the long term.
References
1.
Bacaltchuk J, Hay P (2003), Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 4:CD003391 [update].
2.
Braun DL, Sunday SR, Halmi KA (1994), Psychiatric comorbidity in patients with eating disorders. Psychol Med 24(4):859-867.
3.
Brewerton TD, Lydiard RB, Herzog DB et al. (1995), Comorbidity of axis I psychiatric disorders in bulimia nervosa. J Clin Psychiatry 56(2):77-80.
4.
Bushnell JA, Wells JE, McKenzie JM et al. (1994), Bulimia comorbidity in the general population and in the clinic. Psychol Med 24(3):605-611.
5.
Halmi KA, Agras WS, Mitchell J et al. (2002), Relapse predictors of patients with bulimia nervosa who achieved abstinence through cognitive behavioral therapy. Arch Gen Psychiatry 59(12):1105-1109 [see comments].
6.
Hoopes SP, Reimherr FW, Hedges DW et al. (2003), Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 64(11):1335-1341.
7.
Kaye WH, Nagata T, Weltzin TE et al. (2001), Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 49(7):644-652.
8.
Pike KM, Walsh BT, Vitousek K et al. (2003), Cognitive behavior therapy in the posthospitalization treatment of anorexia nervosa. Am J Psychiatry 160(11):2046-2049.